Mary Ann Chomiak
Medical · Trumbull, CTNPI 1669577953
Payments from drug & device makers
Across 660 payments — averaging $15.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
- Scilex Pharmaceuticals Inc.$2K
- AbbVie$1K
- Collegium Pharmaceutical, Inc.$1K
- Takeda Pharmaceuticals U.S.A., Inc.$945
- Pfizer$517
- plus $3K from 21 others
What the payments were for
- Food & beverage$10,289100%
- Education$260%
- Gifts$00%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 211 | $2,054 |
| Scilex Pharmaceuticals Inc. | 91 | $1,796 |
| AbbVie | 58 | $1,163 |
| Collegium Pharmaceutical, Inc. | 83 | $1,094 |
| Takeda Pharmaceuticals U.S.A., Inc. | 43 | $945 |
| Pfizer | 27 | $517 |
| IBSA Pharma Inc. | 21 | $414 |
| Redhill Biopharma Inc. | 26 | $384 |
| Tersera Therapeutics LLC | 10 | $300 |
| Idorsia Pharmaceuticals US Inc | 16 | $278 |
| Lundbeck LLC | 6 | $179 |
| Amgen | 16 | $168 |
| Biohaven Pharmaceutical Holding Company Ltd. | 7 | $145 |
| Arbor Pharmaceuticals, Inc. | 7 | $125 |
| Eisai Inc. | 7 | $119 |
| GRT US Holding, Inc. | 4 | $104 |
| Biohaven Pharmaceuticals, Inc. | 5 | $94 |
| Almatica Pharma LLC | 5 | $86 |
| Hikma Pharmaceuticals USA | 4 | $63 |
| Axsome Therapeutics, Inc. | 2 | $61 |
| Bioventus LLC | 3 | $52 |
| Valinor Pharma, LLC | 2 | $41 |
| Abbott | 2 | $35 |
| Vertex | 1 | $26 |
| USWM, LLC | 1 | $25 |
| Boston Scientific | 1 | $25 |
| Medtronic | 1 | $21 |
How this compares
$10,315 in reported general payments places this provider in the 95th percentile of 592 medical providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RelistorMethylnaltrexone Bromide | 48 | $105,229 |
| OxycontinOxycodone Hcl | 135 | $56,070 |
| Dermacinrx LidocanLidocaine | 25 | $40,324 |
| Nurtec OdtRimegepant Sulfate | 18 | $35,535 |
| ZtlidoLidocaine | 83 | $32,145 |
| Cyclobenzaprine Hcl | 353 | $30,392 |
| Oxycodone Hcl | 1,481 | $28,194 |
| Lidocaine | 405 | $27,193 |
| TrintellixVortioxetine Hydrobromide | 34 | $23,759 |
| BelbucaBuprenorphine Hcl | 27 | $20,702 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 634 | $20,186 |
| Xtampza ErOxycodone Myristate | 43 | $14,883 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 517 | $13,728 |
| LyricaPregabalin | 14 | $12,782 |
| MovantikNaloxegol Oxalate | 21 | $12,670 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor | $2,054 | $105,22948 claims |
| PfizerNurtec Odt, Lyrica | $517 | $48,31732 claims |
| Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er | $1,094 | $35,58570 claims |
| Scilex Pharmaceuticals Inc.Ztlido | $1,796 | $32,14583 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $945 | $23,75934 claims |
| Hikma Pharmaceuticals USABuprenorphine, Buprenorphine-Naloxone, Morphine Sulfate | $63 | $18,342205 claims |
| Redhill Biopharma Inc.Movantik | $384 | $12,67021 claims |
| AbbVieLinzess | $1,163 | $7,40914 claims |
| Eisai Inc.Dayvigo | $119 | $4,20613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 592 medical providers in Connecticut.
Other medical in Trumbull
- Shilpa DesaiStamford$215K
- Gregory RauNew Haven$211K
- John JasinskiNorwalk$185K
- Brianna PaesanoStamford$153K
- Debra SullivanDerby$100K
- Ryan DonovanNew Haven$75K
- Jonica PagnuccoWaterbury$32K
- Alyssa GreenleafSouthington$26K
- Mark VolpeSuffield$21K
- Josephine DiazSuffield$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.